title: Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
abstract: The Bcr-Abl/p210 fusion protein plays a primary role in the pathogenesis of chronic myelogenous leukemia (CML). Abelson murine leukemia virus, which encodes v-Abl/p160, induces a pre-B cell leukemia/lymphoma in mice. It has been unclear whether the apparent specificity of these two abl oncogenes for myeloid versus lymphoid neoplasms is due to specific intrinsic properties of these Abl oncoproteins, or due to the properties of the target cells expressing them. We have recently shown that expression of Bcr-Abl in bone marrow cells by retroviral transduction efficiently induces a myeloproliferative disorder in mice resembling human CML. In this study, we compared Bcr-Abl/p210 and v-Abl/p160 in this mouse CML model. We found that early in the course of disease, both Bcr-Abl/p210 and v-Abl/p160 expanded early immature hematopoietic cells. Later Bcr-Abl/p210 selectively expanded myeloid cells while v-Abl/p160 primarily induced the rapid in vivo expansion of B lymphoblastic cells, along with a minor population of myeloid cells. In vitro, Bcr-Abl/p210 induced more growth of myeloid colonies from 5-fluorouracil treated bone marrow than v-Abl/p160. These results, obtained under equal bone marrow transduction/transplantation conditions, indicate that Bcr-Abl/p210 has a greater intrinsic capacity than v-Abl/p160 to induce the neoplastic growth of myeloid cells. In addition, we found that cultured cells expressing Bcr-Abl/p210 had more activated STAT5 than cells that expressed v-Abl/p160. This suggests that activation of STAT5 might be one part of the mechanism of abl oncogene disease specificity.
authors.affiliation: Rosenstiel Basic Medical Sciences Research Center, MS029, Department of Biology, Brandeis University, Waltham, MA 02454-9110, USA.
authors.forename: A W
authors.initials: AW
authors.lastname: Gross
authors.forename: R
authors.initials: R
authors.lastname: Ren
mesh_terms: D000818:Animals; D001402:B-Lymphocytes / Q000473:pathology; D002455:Cell Division; D002461:Cell Line, Transformed; D002478:Cells, Cultured; D003114:Colony-Forming Units Assay; D004268:DNA-Binding Proteins / Q000378:metabolism; D016044:Fusion Proteins, bcr-abl / Q000235:genetics / Q000502:physiology*; D006412:Hematopoietic Stem Cells / Q000473:pathology; D016130:Immunophenotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008894:Milk Proteins; D022423:Myeloid Cells / Q000473:pathology*; D016374:Oncogene Proteins v-abl / Q000235:genetics / Q000502:physiology*; D050799:STAT5 Transcription Factor; D015534:Trans-Activators / Q000378:metabolism; D014162:Transfection
chemical_list: D004268:DNA-Binding Proteins; D008894:Milk Proteins; D016374:Oncogene Proteins v-abl; D050799:STAT5 Transcription Factor; D015534:Trans-Activators; D016044:Fusion Proteins, bcr-abl